Monthly Archives: October 2014

Molecular Partners sets the price range for its IPO at CHF 28 to CHF 35 per share

By | Uncategorized | No Comments

Zurich-Schlieren, October 8, 2014. Molecular Partners AG, a clinical-stage biopharmaceutical company focused on the discovery and development of a pioneering class of protein therapeutics called DARPinsâ„¢ for the treatment of severe or life-threatening diseases, announced today the launch of its initial public offering (IPO) on SIX Swiss Exchange with the publication of the offering and listing memorandum and the start of the bookbuilding process.

Read More